6:04 PM
 | 
Apr 25, 2013
 |  BC Extra  |  Company News

Theravance splitting up

Theravance Inc. (NASDAQ:THRX) announced plans late Thursday to split into two publicly traded companies to separate its late-stage, partnered respiratory assets from its R&D. One company -- Royalty Management Co. -- will manage all development and commercial responsibilities plus potential royalty revenues for long-acting adrenergic receptor beta 2 agonist (LABA) products partnered with GlaxoSmithKline plc...

Read the full 266 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >